moatshark My

All holdings

Enovis

ENOV

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$916k
Combined value at quarter end
Last quarter
0 bought
0 sold or trimmed
Price at Q2 ’26 end
$20.70
-9.0% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-4.8%Q3 ’24
+1.9%Q4 ’24
-12.9%Q1 ’25
-17.9%Q2 ’25
-3.3%Q3 ’25
-12.2%Q4 ’25
-14.6%Q1 ’26
-9.0%Q2 ’26
Q3 ’24: -4.8%; Q4 ’24: +1.9%; Q1 ’25: -12.9%; Q2 ’25: -17.9%; Q3 ’25: -3.3%; Q4 ’25: -12.2%; Q1 ’26: -14.6%; Q2 ’26: -9.0%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

2Q4 ’23
2Q1 ’24
2Q2 ’24
2Q3 ’24
2Q4 ’24
2Q1 ’25
2Q2 ’25
2Q3 ’25
2Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 2; Q1 ’24: 2; Q2 ’24: 2; Q3 ’24: 2; Q4 ’24: 2; Q1 ’25: 2; Q2 ’25: 2; Q3 ’25: 2; Q4 ’25: 2; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Enovis.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Enovis
Southeastern Asset Management0.1%$916k$916kUnchanged11 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Enovis
Bought or soldFiling
4 Sep 2026Mcdonald DamienChief Executive Officer▲ Bought13,035$19.15$250kForm 4
4 Sep 2026Engert OliverChief Administrative Officer▲ Bought2,660$18.80$50kForm 4
3 Sep 2026Engert OliverChief Administrative Officer▲ Bought5,140$19.46$100kForm 4
2 Sep 2026Engert OliverChief Administrative Officer▲ Bought2,458$20.32$50kForm 4

About the company

Sector
Health care · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
58m at 31 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$4.2bn2013
$3.4bn2015
$3.3bn2017
$3.3bn2019
$1.4bn2021
$1.7bn2023
$2.2bn2025
2013: $4.2bn; 2014: $4.6bn; 2015: $3.4bn; 2016: $3.2bn; 2017: $3.3bn; 2018: $3.7bn; 2019: $3.3bn; 2020: $1.1bn; 2021: $1.4bn; 2022: $1.6bn; 2023: $1.7bn; 2024: $2.1bn; 2025: $2.2bn
Enovis revenue and net income by year
YearRevenueNet income
2025$2.2bn−$1.2bn
2024$2.1bn−$825m
2023$1.7bn−$33.3m
2022$1.6bn−$13.3m
2021$1.4bn$71.7m
2020$1.1bn$42.6m
2019$3.3bn−$528m
2018$3.7bn$140m
2017$3.3bn$151m
2016$3.2bn$128m
2015$3.4bn$168m
2014$4.6bn$392m
2013$4.2bn$179m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.